Patent SG-11201810549T-A (SG)
Title: Hiv vaccine formulation
Inventor: NGUYEN Thierry-Thien
IPC: A61K39/12
Filed: 2017-06-15
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111011101111111111111111111111111111111111111111111111111111111111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/216288 Al 21 December 2017 (21.12.2017) WIP0 I PCT (51) International Patent Classification: A61K 39/12 (2006.01) A61K 31/198 (2006.01) Published: A61K 31/047 (2006.01) — with international search report (A r t . 21(3)) — with sequence listing part of description (Rule 5.2(a)) (21) International Application Number: PCT/EP2017/064665 (22) International Filing Date: 15 June 2017 (15.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/350,919 16 June 2016 (16.06.2016) US (71) Applicant: JANSSEN VACCINES & PREVENTION B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). (72) Inventors: NGUYEN, Thierry-Thien; Archimedesweg 4-6, 2333 CN Leiden (NL). BRUNER, Mark; Archimedesweg 4-6, 2333 CN Leiden (NL). (74) Agent: VERHAGE, Richard, A et al.; Archimedesweg 4-6, 2333 CN Leiden (NL). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) under Rule 4.17: Declarations as to applicant's entitlement to apply for and be granted a — 1-1 patent (Rule 4.17(ii)) ..! — of inventorship (Rule 4.17(iv)) GC cc el (54) Title: HIV VACCINE FORMULATION 1-1 (57) : Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate ei —. 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated IN temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic © compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, N or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional C HIV antigens.